Published in

BioScientifica, Endocrine-Related Cancer, 2(23), p. 77-91, 2015

DOI: 10.1530/erc-15-0386

Links

Tools

Export citation

Search in Google Scholar

CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer

Journal article published in 2015 by Deborah J. Thompson, _. _., Tracy A. O'Mara, Dylan M. Glubb, Jodie N. Painter, Penelope M. Webb, Timothy Cheng, Elizabeth Folkerd, Deborah Doody, Thompson Dj, Joe Dennis, Jonathan P. Tyrer, O'Mara Ta, Glubb Dm, Maggie Gorman and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Candidate gene studies have reported CYP19A1 variants to be associated with endometrial cancer and with estradiol (E2) concentrations. We analyzed 2937 single nucleotide polymorphisms (SNPs) in 6608 endometrial cancer cases and 37 925 controls and report the first genome wide-significant association between endometrial cancer and a CYP19A1 SNP (rs727479 in intron 2, P=4.8×10−11). SNP rs727479 was also among those most strongly associated with circulating E2 concentrations in 2767 post-menopausal controls (P=7.4×10−8). The observed endometrial cancer odds ratio per rs727479 A-allele (1.15, CI=1.11–1.21) is compatible with that predicted by the observed effect on E2 concentrations (1.09, CI=1.03–1.21), consistent with the hypothesis that endometrial cancer risk is driven by E2. From 28 candidate-causal SNPs, 12 co-located with three putative gene-regulatory elements and their risk alleles associated with higher CYP19A1 expression in bioinformatical analyses. For both phenotypes, the associations with rs727479 were stronger among women with a higher BMI (Pinteraction=0.034 and 0.066 respectively), suggesting a biologically plausible gene-environment interaction.